Literature DB >> 3001220

Human immune response to cytomegalovirus structural polypeptides studied by immunoblotting.

M P Landini, M C Re, G Mirolo, B Baldassarri, M La Placa.   

Abstract

To define better the human immune response to individual structural proteins of human cytomegalovirus (HCMV), 55 human sera with different IgG and IgM titres were studied for their reactivity with HCMV structural polypeptides separated by SDS-PAGE and electrotransferred to nitrocellulose paper. The results obtained showed that antibody titres detected by immunoassay correlate with the intensity and the number of polypeptides reacting by immunoblotting (IB). The IB profiles of HCMV polypeptides reacting with different sera having the same antibody titres show considerable variation. Sera with high levels of IgG antibody and that are IgM-positive frequently react with 155, 149, 82.5, 74.5, 67, 57, 55, 38.5, and 28 kD polypeptides; all these sera react with 155, 67, 57, 55, 38.5 kD polypeptides. Sera with high levels of IgG antibody but that are IgM negative frequently react with all these polypeptides, with the exception of 149 and 74.5. Only 155 and 28 kD polypeptides were recognized by all sera of this group. The sera with moderate levels of IgG antibody preferentially recognize 155, 110, 82.5, 62, 55, 38.5 and 28 kD polypeptides. The sera with low levels of antibody reacted especially with 155 and 62 kD polypeptides. IgM antibody seems to recognize preferentially 155, 110, 67, 57, 55, 38.5 kD polypeptides.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3001220     DOI: 10.1002/jmv.1890170403

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  49 in total

1.  Cytomegalovirus basic phosphoprotein (pUL32) binds to capsids in vitro through its amino one-third.

Authors:  M K Baxter; W Gibson
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

2.  Comparison of immunoblotting with other serological methods and virus isolation for the early detection of primary cytomegalovirus infection in allograft recipients.

Authors:  H Miller; B McCulloch; M P Landini; E Rossier
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

3.  Search for cytomegalovirus-specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays.

Authors:  T Lazzarotto; S Brojanac; G T Maine; M P Landini
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

4.  A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus.

Authors:  B Wagner; B Kropff; H Kalbacher; W Britt; V A Sundqvist; L Ostberg; M Mach
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

5.  Comparison of four techniques for detection of antibodies to cytomegalovirus.

Authors:  Y J Kraat; R M Hendrix; M P Landini; C A Bruggeman
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

6.  Pattern of anti-cytomegalovirus IgM antibodies determined by immunoblotting. A study of kidney graft recipients developing a primary or recurrent CMV infection.

Authors:  J Basson; J C Tardy; M Aymard
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

7.  Antibody response to recombinant lambda gt11 fusion proteins in cytomegalovirus infection.

Authors:  M P Landini; T Lazzarotto; A Ripalti; M X Guan; M La Placa
Journal:  J Clin Microbiol       Date:  1989-10       Impact factor: 5.948

8.  Human cytomegalovirus UL99-encoded pp28 is required for the cytoplasmic envelopment of tegument-associated capsids.

Authors:  Maria C Silva; Qian-Chun Yu; Lynn Enquist; Thomas Shenk
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Human antibody reactivity against the lower matrix protein (pp65) produced by cytomegalovirus.

Authors:  M Ohlin; B Plachter; V A Sundqvist; P G Steenbakkers; J M Middeldorp; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

10.  Site-specific glycosylation of the human cytomegalovirus tegument basic phosphoprotein (UL32) at serine 921 and serine 952.

Authors:  K D Greis; W Gibson; G W Hart
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.